ASX Announcements 2010 ASX Announcements 2009 ASX Announcements 2008 ASX Announcements 2007 ASX Announcements 2006 ASX Announcements 2005 ASX Announcements 2004 ASX Announcements 2003 ASX Announcements 2002 Should you wish to view the report in your browser, you will need to have the Acrobat Reader installed. Please click on the icon (right) and follow the instructions. ASX Announcements 2005 CEO presenting at US Healthcare Conference 09/11/2005   Appendix 3B - Exercise of Options 03/11/2005   Annual General Meeting Results 20/10/2005   Chairman's Address & Managing Director's Presentation 19/10/2005   Appendix 4C - Quarterly Cashflow Report 14/10/2005   Results of Proof of Concept study in psoriasis patients 04/10/2005   Annual Report and Notice of AGM 14/09/2005   Animal Data Supports Therapeutic Potential of ATL1103 in eye diseases 12/09/2005   ATL to submit application to restart ATL1102 Phase IIa trial in MS patients 31/08/2005   Preliminary Final Report - Appendix 4E 12/08/2005   Response to ASX Share Price Query 11/08/2005   Appendix 4C - Quarterly Cashflow Report 21/07/2005   Change of Directors Interest 07/07/2005   Appendix 3B - Issue of Employee Options 07/07/2005   Results of General Meeting 27/06/2005   Notice of General Meeting 25/05/2005   Asthma data presented at American Thoracic Society Meeting 23/05/2005   Investor Update 18/05/2005   Appendix 4C - Quarterly Cashflow Report 19/04/2005   Asthma Data to be Presented at Respiratory Medicines Conference 21/03/2005   Antisense Therapeutics Halts ATL1102 Phase 2a MS Trial 10/03/2005   Market Update 01/03/2005   Antisense Inhibition of VLA-4 in mouse model of MS published 25/02/2005   Appendix 3b - Exercise of Options 22/02/2005   Antisense Therapeutics - US Presentations 18/02/2005   Half Year Report 17/02/2005   Investor Update 02/02/2005   Appendix 4C - Quarterly Cashflow Report 20/01/2005   Antisense Therapeutics Establishes Level 1 US ADR Program 13/01/2005